High Serum Interleukin ‐6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis

ConclusionIL ‐6 may be a prognostic marker of disease progression and severity, and patients with high IL‐6 may be likely to benefit from sarilumab compared with adalimumab or methotrexate. Prospective validation is warranted to confirm the results of these post hoc analyses.

https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41299?af=R

Source: Arthritis and Rheumatology - April 27, 2020 Category: Rheumatology Authors: Anita Boyapati, Sergio Schwartzman, J érôme Msihid, Ernest Choy, Mark C. Genovese, Gerd R. Burmester, Gordon Lam, Toshio Kimura, Jonathan Sadeh, David M. Weinreich, George D. Yancopoulos, Neil M.H. Graham Tags: FULL LENGTH Source Type: research